• Fate Therapeutics is presenting updated Phase 1 FT819 lupus results at ACR Convergence 2026, showing responses without conditioning chemotherapy.
• All three patients with extrarenal lupus treated without conditioning responded; two achieved remission, while the third reached low disease activity.
• Safety findings across 36 patients remained favorable, with no dose-limiting toxicities.
• The first patient receiving two FT819 doses achieved sustained low disease activity, supporting further evaluation of repeat dosing.
• Preclinical FT839 results presented at the meeting support broader immune-cell targeting in rheumatoid arthritis; its Phase 1/2 COMPLETE trial is enrolling.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9874179) on November 10, 2026, and is solely responsible for the information contained therein.